About Aelis Farma

Company Description

Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases.

Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments.

These unique drug candidates, by reproducing a recently discovered natural defense mechanism of the brain , appear to be able to treat various brain pathologies without disrupting normal behavior. A first in pharmacology.

Year founded

2013

Headcount

24

Headquarters

Neurocentre François Magendie 146 Rue Léo Saignat, 33000 Bordeaux – France

Shareholder information

Shares outstanding

12,501,162

IPO

Feb. 18, 2022

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.